Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tianeptine hemioxalate is a novel salt form of the atypical tricyclic antidepressant tianeptine. It is being developed as an extended-release oral tablet for once-daily dosing in the treatment of major depressive disorder. The drug acts primarily by modulating glutamatergic neurotransmission and restoring neuroplasticity in stress-atrophied neurons, rather than through direct effects on monoaminergic neurotransmitter systems. Tianeptine also exhibits weak agonist activity at the μ-opioid receptor, which may contribute to its antidepressant and anxiolytic effects but also carries potential for abuse at high doses. The proprietary formulation aims to improve stability and manufacturability compared to previous salt forms[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tianeptine hemioxalate.